BioCentury | Nov 18, 2019
Finance

How Quan intends to build cross-border start-ups with second fund

...investment was its 2018 participation in a $70 million series B round for Cambridge, U.K.-based Crescendo...
BioCentury | Nov 18, 2019
Finance

How Quan intends to build cross-border start-ups with its second fund

...investment was its 2018 participation in a $70 million series B round for Cambridge, U.K.-based Crescendo...
BioCentury | Sep 5, 2019
Financial News

Quan doubles down with new $250M fund

...for Tempest Therapeutics Inc. (San Francisco, Calif.) and participated in a series B round by Crescendo...
...Centrexion's boards, while Wu is on Crescendo's (see “Versant Launches Tempest With $70M,” “Andera Leads Crescendo’s...
BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

...2018. For example, Takeda has exercised two product rights options under a 2016 collaboration with Crescendo...
...Mentioned Adimab LLC, Lebanon, N.H. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Codiak BioSciences Inc., Cambridge, Mass. Crescendo...
BioCentury | Jul 19, 2019
Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

...Biotech Inc., Kyoto University’s Center for iPS Cell Research and Application (CIRA), protein engineering company Crescendo...
...and Institutions Mentioned Adicet Bio Inc., Menlo Park, Calif. bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Crescendo...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Technology Investment Inc. Immune-based diagnostics, supports judicious antibiotic use to present antibiotic resistance Infectious, inflammation Crescendo...
BioCentury | Feb 16, 2019
Finance

Andera looks early for cancer immunotherapy

...year. The others were late-stage buy-ins, as Andera led a $70 million series B for Crescendo...
...and a £65 million ($84.3 million) series B for Artios Pharma Ltd. (see “Andera Leads Crescendo’s...
BioCentury | Feb 16, 2019
Product Development

ADCs’ inflection point

...antigen-recognition domain until it is cleaved by proteases present only in the tumor microenvironment. B) Crescendo...
...has had is that basically it focused almost exclusively on potency.” Richard Gregory, ImmunoGen Inc. Crescendo...
...sometimes a string of these domains. For a Humabody with a single antigen recognition domain, Crescendo...
BioCentury | Dec 21, 2018
Financial News

Proteomics company Seer launches with $36M

...Proteomics Inc. (San Diego, Calif.) and Affymetrix Inc. vet John Blume as VP of research; Crescendo...
BioCentury | Dec 17, 2018
Company News

Proteomics company Seer launches with $36M

...Proteomics Inc. (San Diego, Calif.) and Affymetrix Inc. vet John Blume as VP of research; Crescendo...
Items per page:
1 - 10 of 121
BioCentury | Nov 18, 2019
Finance

How Quan intends to build cross-border start-ups with second fund

...investment was its 2018 participation in a $70 million series B round for Cambridge, U.K.-based Crescendo...
BioCentury | Nov 18, 2019
Finance

How Quan intends to build cross-border start-ups with its second fund

...investment was its 2018 participation in a $70 million series B round for Cambridge, U.K.-based Crescendo...
BioCentury | Sep 5, 2019
Financial News

Quan doubles down with new $250M fund

...for Tempest Therapeutics Inc. (San Francisco, Calif.) and participated in a series B round by Crescendo...
...Centrexion's boards, while Wu is on Crescendo's (see “Versant Launches Tempest With $70M,” “Andera Leads Crescendo’s...
BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

...2018. For example, Takeda has exercised two product rights options under a 2016 collaboration with Crescendo...
...Mentioned Adimab LLC, Lebanon, N.H. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Codiak BioSciences Inc., Cambridge, Mass. Crescendo...
BioCentury | Jul 19, 2019
Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

...Biotech Inc., Kyoto University’s Center for iPS Cell Research and Application (CIRA), protein engineering company Crescendo...
...and Institutions Mentioned Adicet Bio Inc., Menlo Park, Calif. bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Crescendo...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Technology Investment Inc. Immune-based diagnostics, supports judicious antibiotic use to present antibiotic resistance Infectious, inflammation Crescendo...
BioCentury | Feb 16, 2019
Finance

Andera looks early for cancer immunotherapy

...year. The others were late-stage buy-ins, as Andera led a $70 million series B for Crescendo...
...and a £65 million ($84.3 million) series B for Artios Pharma Ltd. (see “Andera Leads Crescendo’s...
BioCentury | Feb 16, 2019
Product Development

ADCs’ inflection point

...antigen-recognition domain until it is cleaved by proteases present only in the tumor microenvironment. B) Crescendo...
...has had is that basically it focused almost exclusively on potency.” Richard Gregory, ImmunoGen Inc. Crescendo...
...sometimes a string of these domains. For a Humabody with a single antigen recognition domain, Crescendo...
BioCentury | Dec 21, 2018
Financial News

Proteomics company Seer launches with $36M

...Proteomics Inc. (San Diego, Calif.) and Affymetrix Inc. vet John Blume as VP of research; Crescendo...
BioCentury | Dec 17, 2018
Company News

Proteomics company Seer launches with $36M

...Proteomics Inc. (San Diego, Calif.) and Affymetrix Inc. vet John Blume as VP of research; Crescendo...
Items per page:
1 - 10 of 121